EYWN Stock Chart & Stats
€90.70
€2.30(2.19%)
At close: 4:00 PM EST
€90.70
€2.30(2.19%)
Day’s Range― - ―
52-Week Range€63.10 - €130.60
Previous CloseN/A
Volume0.00
Average Volume (3M)11.00
Market Cap
€8.16B
Enterprise Value€13.00K
Total Cash (Recent Filing)€657.70M
Total Debt (Recent Filing)€421.80M
Price to Earnings (P/E)17.6
Beta0.51
Next Earnings
Mar 04, 2027EPS Estimate
2.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.93
Shares Outstanding118,361,220
10 Day Avg. Volume1
30 Day Avg. Volume11
Financial Highlights & Ratios
PEG Ratio-4.00
Price to Book (P/B)3.17
Price to Sales (P/S)3.20
P/FCF Ratio28.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€76.71Price Target Upside-15.42% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)4.36
Revenue Forecast (FY)€4.13B
Bulls Say, Bears Say
Bulls Say
EarningsOrganic growth for the quarter was 10.3% vs 8.4% for consensus.
Financial PerformanceOrganic growth was much stronger, driving an uplift in the full-year guidance.
Bears Say
Market CompetitionBIOFIRE installed base growth slowdown may be debated.
bioMerieux News
EYWN FAQ
What was bioMerieux’s price range in the past 12 months?
bioMerieux lowest stock price was €63.10 and its highest was €130.60 in the past 12 months.
What is bioMerieux’s market cap?
bioMerieux’s market cap is €8.16B.
When is bioMerieux’s upcoming earnings report date?
bioMerieux’s upcoming earnings report date is Mar 04, 2027 which is in 213 days.
How were bioMerieux’s earnings last quarter?
bioMerieux released its earnings results on Jul 28, 2026. The company reported €1.99 earnings per share for the quarter, missing the consensus estimate of €2.03 by -€0.04.
Is bioMerieux overvalued?
According to Wall Street analysts bioMerieux’s price is currently Overvalued.
Does bioMerieux pay dividends?
bioMerieux does not currently pay dividends.
What is bioMerieux’s EPS estimate?
bioMerieux’s EPS estimate is 2.54.
How many shares outstanding does bioMerieux have?
bioMerieux has 118,361,220 shares outstanding.
What happened to bioMerieux’s price movement after its last earnings report?
bioMerieux reported an EPS of €1.99 in its last earnings report, missing expectations of €2.03. Following the earnings report the stock price went down -9.664%.
Which hedge fund is a major shareholder of bioMerieux?
Currently, no hedge funds are holding shares in DE:EYWN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
bioMerieux
bioMérieux S.A. is a global entity operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, specializing in the development and production of in vitro diagnostic solutions. The company's sophisticated systems utilize biological samples to identify infectious diseases, cardiovascular conditions, and various forms of cancer. Additionally, bioMérieux provides essential microbiological testing services for the manufacturing sectors, primarily serving the food, pharmaceutical, cosmetics, and veterinary industries. Its client base includes clinical and hospital laboratories, medical practitioners, blood banks, and industrial quality control facilities. Founded in 1963, originally under the name B-D Mérieux, bioMérieux S.A. maintains its headquarters in Marcy l'Etoile, France, and functions as a subsidiary of Institut Mérieux SA.
EYWN Stock 12 Month Forecast
Average Price Target
€76.71
▼(-15.42% Downside)
Technical Analysis
Eurofins Scientific
―
Sartorius Stedim Biotech
―
Virbac SA
―
Eurofins-Cerep SA
―
Biosynex SA
―